Infectious Diseases (all articles)
Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)
23 Feb, 2021 | 01:57h | UTC
Identifying COVID-19 risk through observational studies to inform control measures
23 Feb, 2021 | 02:01h | UTCIdentifying COVID-19 Risk Through Observational Studies to Inform Control Measures – JAMA
Commentaries on Twitter
20% of infected individuals estimated to cause about 80% of SARS-CoV-2 transmissions. About 50% of transmissions are thought to occur from asymptomatic or pre symptomatic persons. Key lessons learned from #COVID19 epidemiology. Via @JAMA_current https://t.co/AIW1e6Xgy2 pic.twitter.com/oBR4V2opp5
— Muin J. Khoury (@MuinJKhoury) February 22, 2021
Compared w well-ventilated outdoor spaces, #coronavirus infection risk is higher in poorly ventilated indoor spaces w prolonged close contact (within 6 feet of others for 15 min over 24h) + inconsistent use of masks https://t.co/nVFsq2c2CQ @CDCgov @CDCMMWR
— JAMA (@JAMA_current) February 22, 2021
Editorial: Prophylactic anticoagulation for patients in hospital with covid-19
23 Feb, 2021 | 01:59h | UTCProphylactic anticoagulation for patients in hospital with covid-19 – The BMJ
Related: Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials AND Cohort study: Early initiation of prophylactic anticoagulation linked to reduced mortality in patients admitted to hospital with Covid-19
What makes new variants of SARS-CoV-2 concerning is not where they come from, but the mutations they contain
23 Feb, 2021 | 01:56h | UTCRelated: The world needs a single naming system for coronavirus variants – Nature AND Why the WHO won’t call it the ‘U.K. variant’, and you shouldn’t either – CTV News
M-A: Asthma does not increase the risk of infection, hospitalization, ICU admission, and mortality from COVID-19
23 Feb, 2021 | 01:44h | UTCCommentary: Study: Asthma does not increase risk of severe illness or death from COVID-19 – News Medical
Can COVID vaccines stop transmission? Scientists race to find answers
23 Feb, 2021 | 01:42h | UTCCan COVID vaccines stop transmission? Scientists race to find answers – Nature
Related: Fauci: There’s evidence COVID-19 vaccines don’t just protect you — they may stop you from spreading the virus to others, too – Insider AND [Preprint] Covid-19 vaccination associated with reduced viral load, may reduce transmission (study and commentary)
WHO announces updates on new molecular assays for the diagnosis of tuberculosis (TB) and drug resistance
21 Feb, 2021 | 22:05h | UTC
Russia tells WHO it has detected first case of avian flu strain in humans
21 Feb, 2021 | 22:08h | UTCRussia tells WHO it has detected first case of avian flu strain in humans – CNN
See also: Bird flu: Russia detects first case of H5N8 bird flu in humans – BBC AND Russia reports world’s first case of human infection with H5N8 bird flu – Reuters
Opinion – Is it time to delay second doses of coronavirus vaccines?
21 Feb, 2021 | 22:39h | UTCIs it time to delay second doses of coronavirus vaccines? – CNN
3-month interval between first and second dose of Oxford COVID-19 vaccine results in higher vaccine efficacy than 6-week interval
21 Feb, 2021 | 22:42h | UTC
Opinion – Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
21 Feb, 2021 | 22:38h | UTCDelayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture? – The Lancet
Study: One Pfizer/BioNTech shot gives 85% Covid protection
21 Feb, 2021 | 22:41h | UTCOne Pfizer/BioNTech shot gives 85% Covid protection – study – The Guardian
Original study: Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients – The Lancet
Commentary on Twitter
NEW Correspondence reports early findings from study of #Pfizer #vaccine in health-care workers in Israel, suggesting early reductions in #COVID19 infection and symptomatic rates following first dose. Read https://t.co/ONU8bS3Iwo pic.twitter.com/BDDvA7Juyb
— The Lancet (@TheLancet) February 19, 2021
Pfizer vaccine doesn’t need ultra-cold storage after all, company says
21 Feb, 2021 | 22:37h | UTCPfizer vaccine doesn’t need ultra-cold storage after all, company says – ARS Technica
News release: PFIZER AND BIONTECH SUBMIT COVID-19 VACCINE STABILITY DATA AT STANDARD FREEZER TEMPERATURE TO THE U.S. FDA
Commentary on Twitter
🔥Pfizer BioNTech announced submission of new data to the U.S. FDA demonstrating the stability of their COVID-19 vaccine when stored at -25°C to -15°C (-13°F to 5°F), temperatures more commonly found in pharmaceutical freezers and refrigerators🔥https://t.co/egFsSe4oBB
— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) February 19, 2021
Twelve criteria for the development and use of COVID-19 vaccine passports
21 Feb, 2021 | 22:36h | UTCTwelve criteria for the development and use of COVID-19 vaccine passports – The Royal Society
Commentaries: Vaccine passports can work, but face 12 challenges – University of Oxford AND UK scientists highlight 12 criteria for Covid vaccine passports – The Guardian
See also: What place should COVID-19 vaccine passports have in society? – Ada Lovelace Institute AND WHO looks at possible ‘e-vaccination certificates’ for travel – Reuters
Intensive care management of patients with COVID-19: a practical approach
21 Feb, 2021 | 22:34h | UTCRelated Guideline: Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update AND Infographic
Coronapod: our future with an ever-present coronavirus
21 Feb, 2021 | 22:32h | UTCCoronapod: our future with an ever-present coronavirus – Nature
Long Covid: Sequelae in adults at 6 Months after COVID-19 infection
21 Feb, 2021 | 22:13h | UTCSequelae in Adults at 6 Months After COVID-19 Infection – JAMA Network Open
Commentaries: Almost a third of people with ‘mild’ COVID-19 still battle symptoms months later, study finds – CNN AND Nearly One Third of Covid-19 Survivors Have Symptoms, Some Up To 9 Months Later, New Study Finds – Forbes
Commentary on Twitter
Long COVID:
~1/3 of COVID-19 pts had lingering symptoms of a median of 6 mths after infection onset.Among pts whose infections ranged from asymptomatic to severe, 2 problems — fatigue & loss of smell/taste persisted most frequently.https://t.co/xoaWwskPnP
— Christopher Lee (@chriskc_Lee) February 20, 2021
SR: Multisystem inflammatory syndrome in children related to COVID-19
21 Feb, 2021 | 22:11h | UTC
Commentary on Twitter (thread – click for more)
Very proud to present our systematic review on the hyperinflammatory syndrome associated with SARS-CoV-2 in children #PIMS_TS #MISC, as published today in @EurJPediatrics.
We analyzed and summarized over 950 cases from more than 60 records. https://t.co/jO3te1KUIE
(1/n) pic.twitter.com/6BwEw7qFzi
— Levi Hoste (@LeviHoste) February 18, 2021
Global guideline for the diagnosis and management of rare mold infections
19 Feb, 2021 | 02:18h | UTC
Commentary on Twitter
🔥🔥🔥 Global Guideline for Rare Moulds. Endorsed by 55 scientific societies in the field.
All you need to know about Diagnosis and Treatment of Rare Mould infections: from Fusarium to Purpureocillium. @eurconfmedmycol @ISHAM_Mycology @ASMicrobiology
https://t.co/YJ3BX58osW pic.twitter.com/nrAGZl5ox4— Martin Hoenigl🇺🇦🇦🇹 (@martinhoenigl) February 16, 2021
WHO call to action: Vaccine equity declaration – We must accelerate vaccine equity for all health workers – Now
19 Feb, 2021 | 03:03h | UTCCall to Action: Vaccine Equity Declaration – World Health Organization
A single dose of the Pfizer–BioNTech vaccine is 92.6% effective in preventing Covid-19. Is delaying the second dose to get more people vaccinated an alternative?
19 Feb, 2021 | 02:59h | UTCSafety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine – New England Journal of Medicine
Commentary: Researchers urge delaying Pfizer vaccine’s second dose as first highly effective – Reuters
Covid-19: In vitro studies show Pfizer-BioNTech and Moderna vaccines produce fewer antibodies against South African variant
19 Feb, 2021 | 03:01h | UTCCommentaries: Expert reaction to two NEJM Correspondence articles on in vitro studies of the Pfizer-BioNTech and Moderna vaccines and different variants/mutations including mutations on the South Africa variant – Science Media Centre AND Lab studies suggest Pfizer, Moderna vaccines can protect against coronavirus variant – CNN AND Pfizer and Moderna vaccines have reduced effectiveness against South African variant, newly published studies show – The Washington Post AND Pfizer, Moderna vaccines less effective against South African COVID variant – MedicalXpress
Commentary on Twitter
New reports @NEJM today confirming some immune evasion of the B.1.351 variant (identified in South Africa) to both the mRNA vaccines, in vitro data @BioNTech_Group/@Pfizer and @moderna_tx. Less vaccine efficacy vs B.1.351 has been confirmed in clinical trials for 3 vaccines pic.twitter.com/2N7eKDllso
— Eric Topol (@EricTopol) February 17, 2021
Years of life lost to COVID-19 in 81 countries
19 Feb, 2021 | 02:55h | UTCYears of life lost to COVID-19 in 81 countries – Scientific Reports
News release: COVID-19: Over 20.5 million years of life may have been lost due to COVID-19
Commentaries: Expert reaction to study estimating years of life lost globally to COVID-19 – Science Media Centre AND 20.5m years of life may have been lost to Covid across 81 countries, study finds – The Guardian
What does 95% COVID-19 vaccine efficacy really mean?
19 Feb, 2021 | 02:58h | UTCWhat does 95% COVID-19 vaccine efficacy really mean? – The Lancet Infectious Diseases
Related: Pfizer vaccine: what an ‘efficacy rate above 90%’ really means – The Conversation
COVID‐19 convalescent plasma: Interim recommendations from the AABB
19 Feb, 2021 | 02:56h | UTCCOVID‐19 convalescent plasma: interim recommendations from the AABB – Transfusion
News release: AABB panel issues interim recommendations for Covid-19 convalescent plasma use